Sartorius Stedim Biotech Balance Sheet Health
Financial Health criteria checks 3/6
Sartorius Stedim Biotech has a total shareholder equity of €2.7B and total debt of €3.6B, which brings its debt-to-equity ratio to 133.5%. Its total assets and total liabilities are €7.7B and €5.1B respectively. Sartorius Stedim Biotech's EBIT is €468.7M making its interest coverage ratio 4.3. It has cash and short-term investments of €126.1M.
Key information
133.5%
Debt to equity ratio
€3.57b
Debt
Interest coverage ratio | 4.3x |
Cash | €126.10m |
Equity | €2.67b |
Total liabilities | €5.07b |
Total assets | €7.74b |
Recent financial health updates
Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?
Dec 01Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Aug 23Sartorius Stedim Biotech (EPA:DIM) Seems To Use Debt Quite Sensibly
May 25Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly
Feb 07Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet
Nov 09We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt
Jul 26Recent updates
Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)
Feb 19Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear
Dec 22Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?
Dec 01Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?
Nov 10Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Aug 23Sartorius Stedim Biotech (EPA:DIM) Seems To Use Debt Quite Sensibly
May 25Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Is Well Worth Watching
May 09Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?
Apr 23Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly
Feb 07Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?
Jan 20Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet
Nov 09Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today
Oct 20Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Oct 03We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt
Jul 26Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?
Jul 09Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 21Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt
Apr 21Here's Why I Think Sartorius Stedim Biotech (EPA:DIM) Is An Interesting Stock
Apr 03We Like Sartorius Stedim Biotech's (EPA:DIM) Earnings For More Than Just Statutory Profit
Feb 24Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?
Dec 04Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt
Aug 21Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?
May 10Sartorius Stedim Biotech S.A.'s (EPA:DIM) CEO Will Probably Have Their Compensation Approved By Shareholders
Mar 17Here's What Sartorius Stedim Biotech S.A.'s (EPA:DIM) Shareholder Ownership Structure Looks Like
Mar 14Financial Position Analysis
Short Term Liabilities: DIM's short term assets (€1.4B) exceed its short term liabilities (€937.3M).
Long Term Liabilities: DIM's short term assets (€1.4B) do not cover its long term liabilities (€4.1B).
Debt to Equity History and Analysis
Debt Level: DIM's net debt to equity ratio (128.7%) is considered high.
Reducing Debt: DIM's debt to equity ratio has increased from 12.7% to 133.5% over the past 5 years.
Debt Coverage: DIM's debt is well covered by operating cash flow (20.9%).
Interest Coverage: DIM's interest payments on its debt are well covered by EBIT (4.3x coverage).